Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.

Harmony Biosciences has named Adam Zaeske its next chief commercial officer, luring the Takeda veteran back from Europe to lead a push to turn Wakix into a blockbuster and prepare to launch other ...

Puma Biotechnology offers runway stability but lacks clear growth drivers amid drug headwinds and pipeline gaps. Find out why ...

Meanwhile, Morrow pointed to the Japanese drugmaker’s successful partnership with Hong Kong-based Hutchmed, in which Takeda paid $400 million upfront for commercial rights outside of China to a ...

The UK’s health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended brentuximab ...

Harmony Biosciences (HRMY) announced the appointment of Adam Zaeske as executive VP and chief commercial officer, effective March 31. The ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

The biotech has launched a strategic review to consider options, including a possible sale, following shareholder pressure.

“She is a seasoned leader whose extensive operational and commercial experience will be ... Unit and a member of the Executive Team at Takeda, where she oversees a global portfolio of therapies ...

Global pharma giants establish GCCs in India for digital transformation, leveraging tech talent, political stability, and ...

“I am pleased to welcome Teresa to our Board of Directors,” said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. “She is a seasoned leader whose extensive operational and ...

From spinning out Takeda’s China assets to acquiring South Korea’s Hugel, CBC is building a global M&A engine with execution at its core.